Capital Com MENA Securities Trading LLC is regulated by the Capital Market Authority.
Open platformOpen platform

Ascletis' ASC30 cuts HbA1c by up to 1.7% versus placebo in Phase II diabetes trial

By Public Technologies
  • Ascletis Pharma reported positive Phase II results for oral diabetes treatment ASC30, which met its primary endpoint and all secondary endpoints.
  • The once-daily tablet significantly reduced blood sugar levels versus placebo, while also delivering weight loss in participants with type 2 diabetes.
  • No participants discontinued treatment because of gastrointestinal adverse events; no liver safety signals or drug-related serious adverse events were observed.
  • A separate global Phase III program for obesity is enrolling approximately 4,600 participants across two pivotal trials.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascletis Pharma Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN83118) on October 28, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.